Overview
In 2026, Japan is implementing a structural change in its drug designation process. The new workflow allows companies to apply for the “Drug for Specific Use” classification directly to the PMDA (Pharmaceuticals and Medical Devices Agency), eliminating previous ministerial bureaucratic hurdles and accelerating the arrival of treatments for rare and critical diseases in the Japanese market.
Introduction
Japan has historically faced the challenge of “drug loss”—the delay or absence of innovative global medicines in its territory due to regulatory complexity. To reverse this trend, the Ministry of Health, Labour and Welfare (MHLW) and the PMDA have joined forces to create a shorter, more efficient path.
Starting in mid-2026, the new flow for “Specific Use Drugs” comes into effect. This update is a direct invitation for global biopharmaceutical companies to reconsider Japan as a priority in their launch schedules, offering an express route for therapies addressing unmet medical needs.
What Changes in the Designation Flow
Under the previous system, companies relied on a preliminary consultation and recommendation from a ministerial council before starting an in-depth technical dialogue with the PMDA.
- The New Path: Now, companies can present evidence of “unmet medical need” directly to the PMDA.
- Agility: The PMDA takes the lead in the initial technical assessment, allowing the designation to occur concurrently with clinical development, saving months—or even years—of administrative waiting.
Criteria for "Drug for Specific Use"
To qualify for this new flow, a medicine must meet rigorous requirements:
- Severity of the Disease: Intended for life-threatening diseases or those causing severe and progressive disability.
- Therapeutic Superiority: Must demonstrate significantly higher efficacy than existing treatments or fill a gap where no treatment is currently available.
- Feasibility in Japan: A development plan that demonstrates the company’s commitment to the Japanese market.
Strategic Benefits for Companies
- By obtaining this designation via the PMDA, companies can benefit from:
- Priority Consultations: Direct access to agency reviewers to align clinical trial protocols.
- Accelerated Review: A drastic reduction in the analysis time of the final registration dossier.
- Incentive Advantages: Possibility of exclusivity extensions and support in pricing processes.
Conclusion
The decentralization of the designation for specific use drugs in Japan is a clear signal that the country aims to be a leader in innovation in 2026. By removing the exclusive dependence on the prior ministerial council, the PMDA makes the process more technical and predictable.
GRP can act as your local Agent & Register your product in U.S
Contact our team today to Inquire!
Email: info@globalregulatorypartners.com
Telephone : (+1) 781-672-4200
References
Learn more about.
- PMDA (Pharmaceuticals and Medical Devices Agency). New Regulatory Pathways for Unmet Medical Needs. Tokyo, Japan, 2026.
- MHLW (Ministry of Health, Labour and Welfare). Update on the Pharmaceuticals and Medical Devices Act (PMD Act) – 2026 Amendments.
- JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION (JPMA). Strategy for Accelerating Drug Discovery and Access in Japan.
- GLOBAL REGULATORY PARTNERS (GRP). Strategic Insight: Navigating the Japanese PMDA in 2026.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations.
